Ultra-long-acting basal insulin reduces blood glucose variability and hypoglycaemia risk in the elderly
Hypoglycaemia and large fluctuations in blood glucose levels impact elderly patients with diabetes to a greater extent and more adversely than younger adult patients. In addition, age-related conditions and other comorbidities make diabetes management in the elderly even more challenging. A new-generation ultra-long-acting basal insulin analogue allows once-daily dosing and flexible timing of administration without compromising glycaemic control. In an interview with MIMS Doctor, Dr Jenny Lee, Specialist in Geriatrics Medicine in Hong Kong, discussed the value of these features in the management of elderly patients with type 2 diabetes mellitus (T2DM). 

New Molecule

7 New

New Formulation

1 New

New Indication

4 New

Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in